CSO of Biologics at Glenmark Pharma: On India strategy | Q&A

Mint 2018-02-16

Views 5

Mint met with Michael Buschle, Chief Scientific Officer & President of Biologics, Glenmark Pharmaceuticals to discuss costs, challenges and selecting regions for trials in India.
Show more

Share This Video


Download

  
Report form
RELATED VIDEOS
Reporter's Notebook | India poised to be among top 10 pharma markets by 2016
play
01:15

Reporter's Notebook | India poised to be among top 10 pharma markets by 2016
Alactel One Touch Country Manager on India strategy | Q&A
play
01:34

Alactel One Touch Country Manager on India strategy | Q&A
Michael Halbherr on Nokia's HERE India strategy
play
02:25

Michael Halbherr on Nokia's HERE India strategy
CEO of Milacron on India strategy | Q&A
play
00:57

CEO of Milacron on India strategy | Q&A
HCL Tech CEO: On IMS, FY15 and India strategy | Q&A
play
03:10

HCL Tech CEO: On IMS, FY15 and India strategy | Q&A
HTC's strategy in India | Q&A
play
03:11

HTC's strategy in India | Q&A
Dell's Suresh Vaswani on India strategy
play
02:38

Dell's Suresh Vaswani on India strategy
Carmakers in India are adopting a differentiated product strategy
play
01:55

Carmakers in India are adopting a differentiated product strategy
Auto Expo 2014 | Honda scooters' India sales strategy
play
02:29

Auto Expo 2014 | Honda scooters' India sales strategy
L&T Infotech CEOs on growth strategy for India
play
02:03

L&T Infotech CEOs on growth strategy for India
Pharma companies versus trade association
play
01:49

Pharma companies versus trade association
GSK Pharma parent makes open offer
play
02:55

GSK Pharma parent makes open offer